Neurofibromatosis Type 1 with Highly Active Relapsing-Remitting Multiple Sclerosis (RRMS).

Multiple sclerosis case report natalizumab neurofibromatosis 1 neurorehabilitation

Journal

European journal of case reports in internal medicine
ISSN: 2284-2594
Titre abrégé: Eur J Case Rep Intern Med
Pays: Italy
ID NLM: 101648453

Informations de publication

Date de publication:
2021
Historique:
received: 06 12 2020
accepted: 23 12 2020
entrez: 26 3 2021
pubmed: 27 3 2021
medline: 27 3 2021
Statut: epublish

Résumé

Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disease which confers an increased risk of malignant tumour development. Relapsing remitting multiple sclerosis (RRMS) is an inflammatory demyelinating disease of the central nervous system. The coexistence of multiple sclerosis and NF1 is rare but has been reported. Here, we describe the case of a 31-year-old man with NF1 and subacute walking problems with proximal pain in the lower limbs who was successfully treated with natalizumab. The coexistence of multiple sclerosis (MS) and neurofibromatosis type 1 (NF1) is very rare but has been described in the literature.Follow-up of patients with NF1 is important as the early detection and management of MS can prevent further disability.Appropriate treatment and physical therapy can improve the patient's activity and social life.

Identifiants

pubmed: 33768065
doi: 10.12890/2021_002190
pii: 2190-1-20031-1-10-20210201
pmc: PMC7977044
doi:

Types de publication

Journal Article

Langues

eng

Pagination

002190

Informations de copyright

© EFIM 2021.

Déclaration de conflit d'intérêts

Conflicts of Interests: FC received travel grants and modest honoraria for membership of advisory boards from Almirall, Sanofi, Merck and Biogen

Références

J Neurol Neurosurg Psychiatry. 2001 Nov;71(5):679-81
pubmed: 11606684
Brain. 2015 Nov;138(Pt 11):3275-86
pubmed: 26362907
Orphanet J Rare Dis. 2020 Jul 14;15(1):186
pubmed: 32664938
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Mult Scler Relat Disord. 2019 Jul;32:66-69
pubmed: 31048186
Mult Scler. 2009 Sep;15(9):1126-30
pubmed: 19692435

Auteurs

Silvia Ciotti (S)

USL Umbria 2, Department of Rehabilitation, S.C.R.I.N. Trevi, Italy.

Antonella Cometa (A)

USL Umbria 2, Department of Rehabilitation, S.M. Stella, Orvieto, Italy.

Claudia De Carlo (C)

USL Umbria 2, Department of Rehabilitation, Domus Gratiae, Terni, Italy.

Giancarlo Martini (G)

USL Umbria 2, Department of Rehabilitation, Ospedale di Cascia, Italy.

Andrea Marona (A)

USL Umbria 2, Department of Neuroradiology, Ospedale S.G. Battista di Foligno, Italy.

Laura Filippetti (L)

USL Umbria 2, Department of Rehabilitation, S.C.R.I.N. Trevi, Italy.

Diego Carducci (D)

USL Umbria 2, Department of Rehabilitation and Neurology, Ospedale S.G. Battista di Foligno, Italy.

Silvano Baratta (S)

USL Umbria 2, Department of Rehabilitation, S.C.R.I.N. Trevi, Italy.

Mauro Zampolini (M)

USL Umbria 2, Department of Rehabilitation and Neurology, Ospedale S.G. Battista di Foligno, Italy.

Francesco Corea (F)

USL Umbria 2, Department of Rehabilitation, S.C.R.I.N. Trevi, Italy.

Classifications MeSH